You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCarbamazepine
Accession NumberDB00564  (APRD00337)
TypeSmall Molecule
GroupsApproved, Investigational
Description

An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. [PubChem]

Structure
Thumb
Synonyms
SynonymLanguageCode
5-Carbamoyl-5H-dibenz(b,f)azepineNot AvailableNot Available
5-Carbamoyl-5H-dibenz[b,F]azepineNot AvailableNot Available
5-Carbamoyl-5H-dibenzo(b,F)azepineNot AvailableNot Available
5-Carbamyl-5H-dibenzo(b,F)azepineNot AvailableNot Available
5H-Dibenz(b,F)azepine-5-carboxamideNot AvailableNot Available
CarbamazepenNot AvailableNot Available
CarbamazepinGermanINN
CarbamazepinaSpanishINN
CarbamazépineFrenchINN
CarbamazepinumLatinINN
CBZNot AvailableNot Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Tegretoltablet, chewable100 mgoralNovartis Pharmaceuticals Corporation1981-12-14Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tegretolsuspension100 mg/5mLoralNovartis Pharmaceuticals Corporation1987-12-18Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tegretoltablet200 mgoralNovartis Pharmaceuticals Corporation1968-03-11Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tegretol XRtablet, extended release100 mgoralNovartis Pharmaceuticals Corporation1996-03-25Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tegretol XRtablet, extended release200 mgoralNovartis Pharmaceuticals Corporation1996-03-25Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tegretol XRtablet, extended release400 mgoralNovartis Pharmaceuticals Corporation1996-03-25Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, extended release200 mgoralKAISER FOUNDATION HOSPITALS2009-10-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepine ERtablet, extended release100 mgoralSandoz Inc1996-03-25Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepine ERtablet, extended release200 mgoralSandoz Inc1996-03-25Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepine ERtablet, extended release400 mgoralSandoz Inc1996-03-25Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Equetrocapsule, extended release100 mgoralValidus Pharmaceuticals LLC2004-12-10Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Equetrocapsule, extended release200 mgoralValidus Pharmaceuticals LLC2004-12-10Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Equetrocapsule, extended release300 mgoralValidus Pharmaceuticals LLC2004-12-10Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbatrolcapsule, extended release100 mgoralShire US Manufacturing Inc.1999-12-22Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbatrolcapsule, extended release200 mgoralShire US Manufacturing Inc.1997-09-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbatrolcapsule, extended release300 mgoralShire US Manufacturing Inc.1997-09-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbatrolcapsule, extended release300 mgoralPhysicians Total Care, Inc.2009-10-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepine ERtablet, extended release400 mgoralPhysicians Total Care, Inc.2009-10-16Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinecapsule, extended release100 mgoralPrasco Laboratories2011-12-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinecapsule, extended release200 mgoralPrasco Laboratories2011-12-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinecapsule, extended release300 mgoralPrasco Laboratories2011-12-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepine ERtablet, extended release200 mgoralAmerican Health Packaging2013-06-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepine ERtablet, extended release400 mgoralAmerican Health Packaging2013-06-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mazepinetablet200 mgoralBiomed 2002 IncNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Epitoltablet200 mgoralTeva Pharmaceuticals USA Inc1990-09-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mgoralTeva Pharmaceuticals USA Inc1990-09-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, chewable100 mgoralTeva Pharmaceuticals USA Inc1995-09-18Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinecapsule, extended release100 mgoralTeva Pharmaceuticals USA Inc2013-07-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinecapsule, extended release200 mgoralTeva Pharmaceuticals USA Inc2013-02-11Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinecapsule, extended release300 mgoralTeva Pharmaceuticals USA Inc2013-02-11Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mgoralActavis Elizabeth LLC1995-01-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mgoralNcs Health Care Of Ky, Inc Dba Vangard Labs1990-09-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet100 mgoralNcs Health Care Of Ky, Inc Dba Vangard Labs2005-12-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mgoralUpsher Smith Laboratories, Inc1996-10-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, chewable100 mgoralMajor Pharmaceuticals2010-03-22Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mgoralMajor Pharmaceuticals2010-09-20Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mgoralTorrent Pharmaceuticals Limited2009-10-23Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, chewable100 mgoralTorrent Pharmaceuticals Limited2009-08-26Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mgoralSTAT Rx USA LLC2009-12-08Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mgoralRebel Distributors Corp2009-07-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinecapsule, extended release300 mgoralNostrum Laboratories, Inc.2011-05-20Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinecapsule, extended release100 mgoralNostrum Laboratories, Inc.2011-05-20Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinecapsule, extended release200 mgoralNostrum Laboratories, Inc.2011-05-20Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mgoralAidarex Pharmaceuticals LLC1996-10-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mgoralPd Rx Pharmaceuticals, Inc.1996-10-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, chewable100 mgoralREMEDYREPACK INC.2011-08-17Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mgoralREMEDYREPACK INC.2010-12-02Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, chewable200 mgoralREMEDYREPACK INC.2013-03-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mgoralREMEDYREPACK INC.2012-09-04Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mgoralREMEDYREPACK INC.2011-05-16Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, chewable100 mgoralREMEDYREPACK INC.2011-07-13Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mgoralUnit Dose Services1996-10-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mgoralMylan Institutional Inc.1995-09-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, chewable100 mgoralMylan Institutional Inc.1996-05-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mgoralTaro Pharmaceuticals U.S.A., Inc.1996-10-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, chewable100 mgoralTaro Pharmaceuticals U.S.A., Inc.2000-10-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinesuspension100 mg/5mLoralTaro Pharmaceuticals U.S.A., Inc.2004-09-20Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, extended release100 mgoralTaro Pharmaceuticals U.S.A., Inc.2009-03-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, extended release200 mgoralTaro Pharmaceuticals U.S.A., Inc.2009-03-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, extended release400 mgoralTaro Pharmaceuticals U.S.A., Inc.2009-03-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinecapsule, extended release300 mgoralTaro Pharmaceuticals U.S.A., Inc.2013-06-21Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinecapsule, extended release200 mgoralTaro Pharmaceuticals U.S.A., Inc.2013-06-21Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinecapsule, extended release100 mgoralTaro Pharmaceuticals U.S.A., Inc.2013-06-21Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mgoralREMEDYREPACK INC.2013-05-08Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, chewable100 mgoralState of Florida DOH Central Pharmacy2013-01-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet100 mgoralState of Florida DOH Central Pharmacy2009-07-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mgoralState of Florida DOH Central Pharmacy2009-07-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mgoralState of Florida DOH Central Pharmacy2009-07-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, extended release400 mgoralState of Florida DOH Central Pharmacy2014-11-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mgoralA S Medication Solutions Llc1996-10-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mgoralPhysicians Total Care, Inc.1993-09-23Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, chewable100 mgoralPhysicians Total Care, Inc.1995-07-27Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mgoralCardinal Health2010-09-20Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, extended release200 mgoralCardinal Health2009-03-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mgoralCardinal Health1996-10-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, chewable100 mgoralCardinal Health2000-10-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, chewable100 mgoralCardinal Health2011-10-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mgoralClinical Solutions Wholesale2009-10-23Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, chewable100 mgoralClinical Solutions Wholesale2009-08-26Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mgoralGolden State Medical Supply, Inc.2014-03-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinesuspension100 mg/5mLoralGolden State Medical Supply, Inc.2004-09-20Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinecapsule, extended release100 mgoralGolden State Medical Supply, Inc.2011-05-20Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinecapsule, extended release200 mgoralGolden State Medical Supply, Inc.2011-05-20Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinecapsule, extended release300 mgoralGolden State Medical Supply, Inc.2011-05-20Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mgoralGolden State Medical Supply, Inc.1996-10-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, chewable100 mgoralGolden State Medical Supply, Inc.2000-10-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinesuspension100 mg/5mLoralMorton Grove Pharmaceuticals, Inc.2002-06-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mgoralApotex Corp.2002-09-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinecapsule, extended release100 mgoralApotex Corp.2012-03-23Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinecapsule, extended release200 mgoralApotex Corp.2012-03-23Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinecapsule, extended release300 mgoralApotex Corp.2012-03-23Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mgoralREMEDYREPACK INC.2014-11-26Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mgoralbryant ranch prepack2011-05-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mgoralTYA Pharmaceuticals1996-10-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mgoralContract Pharmacy Services Pa2010-02-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mgoralAmerican Health Packaging2014-04-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinesuspension200 mg/10mLoralPrecision Dose Inc.2003-09-02Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinesuspension100 mg/5mLoralPrecision Dose Inc.2007-02-27Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mgoralPreferred Pharmaceuticals, Inc.2014-04-02Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, chewable200 mgoralPreferred Pharmaceuticals, Inc2012-04-23Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet200 mgoralMc Kesson Contract Packaging2011-10-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Carbamazepinetablet, chewable100 mgoralMc Kesson Contract Packaging2011-09-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International Brands
NameCompany
ActebralSanofi-Aventis
AnlepticSquare
BistonZentiva
CarbamatAstraZeneca
NeurotopGerot
TEGretol ChewtabsNot Available
TEGretol-CRNovartis
TEGretol-XRNovartis
TerilTaro
TimonilDesitin
VersitolMicro Synapse
VersizurMicro Labs
Brand mixturesNot Available
SaltsNot Available
Categories
CAS number298-46-4
WeightAverage: 236.2686
Monoisotopic: 236.094963016
Chemical FormulaC15H12N2O
InChI KeyFFGPTBGBLSHEPO-UHFFFAOYSA-N
InChI
InChI=1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)
IUPAC Name
2-azatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,9,11,13-heptaene-2-carboxamide
SMILES
NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dibenzazepines. These are compounds with two benzene rings connected by an azepine ring. Azepine is an unsaturated seven-member heterocycle with one nitrogen atom replacing a carbon atom.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzazepines
Sub ClassDibenzazepines
Direct ParentDibenzazepines
Alternative Parents
Substituents
  • Dibenzazepine
  • Azepine
  • Benzenoid
  • Urea
  • Tertiary amine
  • Azacycle
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of epilepsy and pain associated with true trigeminal neuralgia.
PharmacodynamicsCarbamazepine, an anticonvulsant structurally similar to tricyclic antidepressants, is used to treat partial seizures, tonic-clonic seizures, pain of neurologic origin such as trigeminal neuralgia, and psychiatric disorders including manic-depressive illness and aggression due to dementia. The response to carbamazepine is variable and may be due to its variable transport, especially across the blood-brain-barrier. The transporter that may confer drug resistance is RALBP1.
Mechanism of actionCarbamazepine inhibits sustained repetitive firing by blocking use-dependent sodium channels. Pain relief is believed to be associated with blockade of synaptic transmission in the trigeminal nucleus and seizure control with reduction of post-tetanic potentiation of synaptic transmission in the spinal cord. Carbamazepine also possesses anticholinergic, central antidiuretic, antiarrhythmic, muscle relaxant, antidepressant (possibly through blockade of norepinephrine release), sedative, and neuromuscular-blocking properties.
AbsorptionIn clinical studies, carbamazepine suspension, conventional tablets, and extended-release tablets delivered equivalent amounts of drug to the systemic circulation. However, it has been observed that the suspension is somewhat faster absorbed. Furthermore, the extended-release tablet is slightly slower than the conventional tablet. The bioavailability of the extended-release tablet is 89%, compared to the suspension. Plasma levels of carbamazepine are variable. The time to peak concentration for the different formulations are as follows: Suspension = 1.5 hours; Conventional tablets = 4-5 hours; Extended-release tablets = 3-12 hours.
Volume of distributionNot Available
Protein binding76% bound to plasma proteins.
Metabolism

Hepatic. CYP3A4 is the primary isoform responsible for the formation of carbamazepine-10,11-epoxide. This metabolite is active and shown to be equipotent to carbamazepine as an anticonvulsant. Carbamazepine is more rapidly metabolized to the aforementioned metabolite in younger patients than in adults. It also undergoes glucuronidation via UGT2B7, however this finding has been disputed.

SubstrateEnzymesProduct
Carbamazepine
10,11-EpoxycarbamazepineDetails
Carbamazepine
3-hydroxycarbamazepineDetails
Carbamazepine
Not Available
Carbamazepine 2,3-epoxideDetails
3-hydroxycarbamazepine
2,3-DihydroxycarbamazepineDetails
Carbamazepine 2,3-epoxide
Not Available
2-hydroxycarbamazepineDetails
2-hydroxycarbamazepine
2-hydroxyiminostilbeneDetails
2-hydroxyiminostilbene
Not Available
Carbamazepine iminoquinoneDetails
2-hydroxycarbamazepine
Not Available
2,3-DihydroxycarbamazepineDetails
2,3-Dihydroxycarbamazepine
Not Available
Carbamazepine-O-quinoneDetails
10,11-Epoxycarbamazepine
10,11-DihydroxycarbamazepineDetails
Carbamazepine 2,3-epoxide
Not Available
3-hydroxycarbamazepineDetails
Route of elimination72% of the dose is in the urine while 28% is in the feces. Hydroxylated and conjugated metabolites are largely what was recovered in the urine. 3% of the dose is recovered as unchanged carbamazepine.
Half lifeInitial half-life values range from 25-65 hours, decreasing to 12-17 hours on repeated doses.
ClearanceNot Available
ToxicityMild ingestions cause vomiting, drowsiness, ataxia, slurred speech, nystagmus, dystonic reactions, and hallucinations. Severe intoxications may produce coma, seizures, respiratory depression, and hypotension
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Carbamazepine Metabolism PathwayDrug metabolismSMP00634
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Sodium channel protein type 1 subunit alpha
Gene symbol: SCN1A
UniProt: P35498
rs3812718 Not AvailableIVS5N + 5 G>ACarbamazepine resistant therapy, higher maintenance dose24052718
SNP Mediated Adverse Drug Reactions
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeAdverse ReactionReference(s)
Heat shock 70 kDa protein 1-like
Gene symbol: HSPA1L
UniProt: P34931
rs2227956 Not AvailableT alleleHypersensitivity reaction, mild erythematous skin rashes, macropapular eruption, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis16538175
Heat shock 70 kDa protein 1A/1B
Gene symbol: HSPA1A
UniProt: P08107
rs506770 Not AvailableC alleleHypersensitivity reaction, mild erythematous skin rashes, macropapular eruption, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis16538175
Heat shock 70 kDa protein 1A/1B
Gene symbol: HSPA1A
UniProt: P08107
rs1043620 Not AvailableC alleleHypersensitivity reaction, mild erythematous skin rashes, macropapular eruption, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis16538175
HLA class I histocompatibility antigen, B-15 alpha chain
Gene symbol: HLA-B
UniProt: P30464
rs3130690 Not AvailableT alleleStevens-Johnson syndrome (SJS), toxic epidermal necrolysis16538176
HLA class I histocompatibility antigen, A-31 alpha chain
Gene symbol: HLA-A
UniProt: P16189
rs1264511 Not AvailableG alleleMacropapular eruption16538176
Promotilin
Gene symbol: MLN
UniProt: P12872
rs2894342 Not AvailableA alleleHypersensitivity syndrome16538176
Flotillin-1
Gene symbol: FLOT1
UniProt: O75955
rs3909184 HLA-B*1502G > CPatients with the CG or GG genotype (in Asian patients) were at a higher risk of Steven-Johnson Syndrome compared to those with the CC genotype (non-carriers of HLA-b*1502)18637831
Mucin-21
Gene symbol: MUC21
UniProt: Q5SSG8
rs2844682 HLA-B*1502G>APatients with the AG or GG genotype (in Asian patients) were at a higher risk of Steven-Johnson Syndrome compared to those with the AA genotype18637831
Flotillin-1
Gene symbol: FLOT1
UniProt: O75955
rs3909184 HLA-B*1502G > CPatients with the CG or GG genotype (in Asian patients) were at a higher risk of Steven-Johnson Syndrome compared to those with the CC genotype (non-carriers of HLA-b*1502)15057820
Mucin-21
Gene symbol: MUC21
UniProt: Q5SSG8
rs2844682 HLA-B*1502G>APatients with the AG or GG genotype (in Asian patients) were at a higher risk of Steven-Johnson Syndrome compared to those with the AA genotype15057820
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9962
Blood Brain Barrier+0.9958
Caco-2 permeable+0.6538
P-glycoprotein substrateNon-substrate0.6466
P-glycoprotein inhibitor INon-inhibitor0.8748
P-glycoprotein inhibitor IINon-inhibitor0.8381
Renal organic cation transporterNon-inhibitor0.8177
CYP450 2C9 substrateNon-substrate0.7466
CYP450 2D6 substrateSubstrate0.884
CYP450 3A4 substrateNon-substrate0.6204
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 substrateNon-inhibitor0.907
CYP450 2D6 substrateNon-inhibitor0.9232
CYP450 2C19 substrateNon-inhibitor0.9025
CYP450 3A4 substrateNon-inhibitor0.8222
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7358
Ames testNon AMES toxic0.5554
CarcinogenicityNon-carcinogens0.8848
BiodegradationNot ready biodegradable0.978
Rat acute toxicity2.1131 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9653
hERG inhibition (predictor II)Non-inhibitor0.8734
Pharmacoeconomics
Manufacturers
  • Shire development inc
  • Validus pharmaceuticals inc
  • Taro pharmaceutical industries ltd
  • Wockhardt eu operations (swiss) ag
  • Novartis pharmaceuticals corp
  • Taro pharmaceuticals usa inc
  • Cadista pharmaceuticals inc
  • Torrent pharmaceuticals ltd
  • Teva pharmaceuticals usa inc
  • Actavis elizabeth llc
  • Apotex inc etobicoke site
  • Inwood laboratories inc sub forest laboratories inc
  • Pliva inc
  • Usl pharma inc
  • Warner chilcott div warner lambert co
Packagers
Dosage forms
FormRouteStrength
Capsule, extended releaseoral100 mg
Capsule, extended releaseoral200 mg
Capsule, extended releaseoral300 mg
Suspensionoral100 mg/5mL
Suspensionoral200 mg/10mL
Tabletoral100 mg
Tabletoral200 mg
Tablet, chewableoral100 mg
Tablet, chewableoral200 mg
Tablet, extended releaseoral100 mg
Tablet, extended releaseoral200 mg
Tablet, extended releaseoral400 mg
Prices
Unit descriptionCostUnit
Equetro 300 mg capsule2.65USD capsule
TEGretol XR 400 mg 12 Hour tablet2.42USD tablet
Carbamazepine powder2.26USD g
Tegretol xr 400 mg tablet2.19USD tablet
Carbatrol 100 mg 12 Hour Capsule2.18USD capsule
Equetro 200 mg capsule2.15USD capsule
CarBAMazepine 400 mg 12 Hour tablet2.05USD tablet
Carbatrol 300 mg 12 Hour Capsule1.95USD capsule
Carbatrol 200 mg 12 Hour Capsule1.92USD capsule
Carbatrol er 100 mg capsule1.84USD capsule
Carbatrol er 200 mg capsule1.84USD capsule
Carbatrol er 300 mg capsule1.84USD capsule
Equetro 100 mg capsule1.74USD capsule
TEGretol XR 200 mg 12 Hour tablet1.45USD tablet
Tegretol xr 200 mg tablet1.1USD tablet
CarBAMazepine 200 mg 12 Hour tablet1.03USD tablet
TEGretol XR 100 mg 12 Hour tablet0.97USD tablet
Tegretol Cr 400 mg Sustained-Release Tablet0.84USD tablet
Tegretol 200 mg tablet0.75USD tablet
Tegretol xr 100 mg tablet0.55USD tablet
Tegretol Cr 200 mg Sustained-Release Tablet0.42USD tablet
Mylan-Carbamazepine Cr 400 mg Sustained-Release Tablet0.4USD tablet
Pms-Carbamazepine-Cr 400 mg Sustained-Release Tablet0.4USD tablet
Sandoz Carbamazepine Cr 400 mg Sustained-Release Tablet0.4USD tablet
Tegretol 200 mg Chewable Tablet0.34USD tablet
Carbamazepine 200 mg tablet0.31USD tablet
Epitol 200 mg tablet0.3USD tablet
CarBAMazepine 100 mg Chew Tabs0.25USD tab
Mylan-Carbamazepine Cr 200 mg Sustained-Release Tablet0.2USD tablet
Pms-Carbamazepine-Cr 200 mg Sustained-Release Tablet0.2USD tablet
Sandoz Carbamazepine Cr 200 mg Sustained-Release Tablet0.2USD tablet
Tegretol 100 mg Chewable Tablet0.17USD tablet
CarBAMazepine 100 mg/5ml Suspension0.16USD ml
Pms-Carbamazepine 200 mg Chewable Tablet0.16USD tablet
Sandoz Carbamazepine 200 mg Chewable Tablet0.16USD tablet
Taro-Carbamazepine 200 mg Chewable Tablet0.16USD tablet
Apo-Carbamazepine 200 mg Tablet0.08USD tablet
Novo-Carbamaz 200 mg Tablet0.08USD tablet
Nu-Carbamazepine 200 mg Tablet0.08USD tablet
Pms-Carbamazepine 100 mg Chewable Tablet0.08USD tablet
Sandoz Carbamazepine 100 mg Chewable Tablet0.08USD tablet
Taro-Carbamazepine 100 mg Chewable Tablet0.08USD tablet
Tegretol 20 mg/ml Suspension0.08USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
United States52846621994-02-082011-02-08
United States69772532004-05-192024-05-19
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point204-206Schindier, W.; U.S. Patent 2,948,718; August 9, 1960; assigned to Geigy Chemical Corporation.
water solubility17.7 mg/LNot Available
logP2.45DAL POZZO,A ET AL. (1989)
Predicted Properties
PropertyValueSource
Water Solubility0.152 mg/mLALOGPS
logP2.1ALOGPS
logP2.77ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)15.96ChemAxon
pKa (Strongest Basic)-3.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.33 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity71.89 m3·mol-1ChemAxon
Polarizability25 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.72 KB)
SpectraMS1D NMR
References
Synthesis Reference

Ketan Dhansukhlal Vyas, Wajid Sajjad Jafri, Ashok Krishna Kulkarni, “Process for preparing carbamazepine from iminostilbene.” U.S. Patent US6245908, issued February, 1998.

US6245908
General Reference
  1. Staines AG, Coughtrie MW, Burchell B: N-glucuronidation of carbamazepine in human tissues is mediated by UGT2B7. J Pharmacol Exp Ther. 2004 Dec;311(3):1131-7. Epub 2004 Aug 3. Pubmed
  2. Sisodiya SM, Goldstein DB: Drug resistance in epilepsy: more twists in the tale. Epilepsia. 2007 Dec;48(12):2369-70. Pubmed
External Links
ATC CodesN03AF01
AHFS Codes
  • 28:12.92
PDB EntriesNot Available
FDA labelDownload (55.9 KB)
MSDSDownload (71.6 KB)
Interactions
Drug Interactions
Drug
AcenocoumarolMay decrease the serum concentration of Vitamin K Antagonists.
AcetaminophenMay increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.
AcetazolamideMay increase the serum concentration of CarBAMazepine. Exceptions: Brinzolamide; Dorzolamide.
AdenosineCarBAMazepine may enhance the adverse/toxic effect of Adenosine. Specifically, the risk of higher degree heart block may be increased.
AfatinibP-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Afatinib.
AlbendazoleMay decrease serum concentrations of the active metabolite(s) of Albendazole.
AllopurinolAllopurinol may increase the serum concentration of CarBAMazepine.
AminophyllineTheophylline Derivatives may decrease the serum concentration of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Theophylline Derivatives.
AmitriptylineMay increase the metabolism of Tricyclic Antidepressants.
AmlodipineMay increase the metabolism of Calcium Channel Blockers (Dihydropyridine).
AmoxapineMay increase the metabolism of Tricyclic Antidepressants.
ApixabanCYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.
ApremilastCYP3A4 Inducers (Strong) may decrease the serum concentration of Apremilast.
AripiprazoleCYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.
ArtemetherCYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Artemether. Specifically, dihydroartemisinin concentrations may be reduced. CYP3A4 Inducers (Strong) may decrease the serum concentration of Artemether.
AtazanavirMay increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.
AxitinibCYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.
Azilsartan medoxomilThiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.
BatimastatCarBAMazepine may increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.
bazedoxifeneCarBAMazepine may decrease the serum concentration of Bazedoxifene. This may lead to loss of efficacy or, if bazedoxifene is combined with estrogen therapy, an increased risk of endometrial hyperplasia.
BedaquilineCYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.
BendamustineCYP1A2 Inducers (Strong) may decrease the serum concentration of Bendamustine. Concentrations of active metabolites may be increased.
BendroflumethiazideThiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.
BoceprevirCarBAMazepine may decrease the serum concentration of Boceprevir.
BortezomibCYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib.
BosentanMay decrease the serum concentration of CYP3A4 Substrates.
BosutinibCYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.
Brentuximab vedotinCYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.
BuprenorphineCNS Depressants may enhance the CNS depressant effect of Buprenorphine.
ButalbitalMay increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.
CabozantinibCYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.
CanagliflozinCarBAMazepine may decrease the serum concentration of Canagliflozin.
CaspofunginInducers of Drug Clearance may decrease the serum concentration of Caspofungin.
ChlorothiazideThiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.
ChlorthalidoneThiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.
CimetidineCimetidine may increase the serum concentration of CarBAMazepine. The serum carbamazepine concentration might return to normal within one week of starting cimetidine.
CitalopramMay increase the metabolism of Selective Serotonin Reuptake Inhibitors. Specifically those agents metabolized via CYP1A2, 2C, and/or 3A4 isoenzymes. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CarBAMazepine. Specifically those SSRIs that inhibit CYP3A4 isoenzymes.
ClarithromycinCYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.
ClomipramineCarBAMazepine may increase the serum concentration of ClomiPRAMINE.
ClozapineMay enhance the myelosuppressive effect of CloZAPine. CarBAMazepine may decrease the serum concentration of CloZAPine.
ConivaptanMay increase the serum concentration of CYP3A4 Substrates.
CrizotinibCYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.
Dabigatran etexilateP-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Dabigatran Etexilate.
DabrafenibMay decrease the serum concentration of CYP3A4 Substrates.
DanazolMay decrease the metabolism of CarBAMazepine.
DarunavirMay increase the serum concentration of CarBAMazepine.
DasatinibCYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.
DeferasiroxMay decrease the serum concentration of CYP3A4 Substrates.
DelavirdineMay decrease the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of CarBAMazepine. This mechanism applies specifically to efavirenz.
DesipramineMay increase the metabolism of Tricyclic Antidepressants.
DesmopressinMay enhance the adverse/toxic effect of Desmopressin.
DesogestrelMay diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.
DiclofenamideMay increase the serum concentration of CarBAMazepine. Exceptions: Brinzolamide; Dorzolamide.
DihydrocodeineMay increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.
DiltiazemMay decrease the serum concentration of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of CarBAMazepine.
DolutegravirCarBAMazepine may decrease the serum concentration of Dolutegravir.
DoxycyclineMay decrease the serum concentration of Doxycycline.
DoxylamineMay enhance the CNS depressant effect of CNS Depressants.
DronabinolCYP3A4 Inducers (Strong) may decrease the serum concentration of Dronabinol.
DronedaroneCYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.
DroperidolMay enhance the CNS depressant effect of CNS Depressants.
DrospirenoneMay diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.
EliglustatCYP3A4 Inducers (Strong) may decrease the serum concentration of Eliglustat.
EnzalutamideCYP2C8 Inducers (Strong) may decrease the serum concentration of Enzalutamide.
ErlotinibCYP3A4 Inducers (Strong) may decrease the serum concentration of Erlotinib.
EscitalopramMay increase the metabolism of Selective Serotonin Reuptake Inhibitors. Specifically those agents metabolized via CYP1A2, 2C, and/or 3A4 isoenzymes. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CarBAMazepine. Specifically those SSRIs that inhibit CYP3A4 isoenzymes.
Ethinyl EstradiolMay diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.
EthoxzolamideMay increase the serum concentration of CarBAMazepine. Exceptions: Brinzolamide; Dorzolamide.
EthynodiolMay diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.
EtonogestrelMay diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.
EtravirineMay decrease the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of CarBAMazepine. This mechanism applies specifically to efavirenz.
EverolimusCYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.
ExemestaneCYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.
EzogabineCarBAMazepine may decrease the serum concentration of Ezogabine.
FelbamateCarBAMazepine may decrease the serum concentration of Felbamate. Felbamate may decrease the serum concentration of CarBAMazepine.
FelodipineMay increase the metabolism of Calcium Channel Blockers (Dihydropyridine).
FentanylCYP3A4 Inducers (Strong) may decrease the serum concentration of FentaNYL.
FingolimodCarBAMazepine may decrease the serum concentration of Fingolimod.
FluconazoleFluconazole may increase the serum concentration of CarBAMazepine.
FlunarizineCarBAMazepine may decrease the serum concentration of Flunarizine.
FluoxetineMay increase the metabolism of Selective Serotonin Reuptake Inhibitors. Specifically those agents metabolized via CYP1A2, 2C, and/or 3A4 isoenzymes. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CarBAMazepine. Specifically those SSRIs that inhibit CYP3A4 isoenzymes.
FluvoxamineMay increase the metabolism of Selective Serotonin Reuptake Inhibitors. Specifically those agents metabolized via CYP1A2, 2C, and/or 3A4 isoenzymes. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CarBAMazepine. Specifically those SSRIs that inhibit CYP3A4 isoenzymes.
FosamprenavirMay increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.
FosphenytoinCarBAMazepine may decrease the serum concentration of Fosphenytoin. CarBAMazepine may increase the serum concentration of Fosphenytoin. Possibly by competitive inhibition at sites of metabolism. Fosphenytoin may decrease the serum concentration of CarBAMazepine.
GefitinibCYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.
GuanfacineCYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.
HaloperidolMay increase the metabolism of Haloperidol.
HydrochlorothiazideThiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.
HydrocodoneCNS Depressants may enhance the CNS depressant effect of Hydrocodone.
HydroxyzineMay enhance the CNS depressant effect of CNS Depressants.
ImatinibCYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.
IndapamideThiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.
IndinavirMay increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.
IrinotecanCYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Irinotecan. Specifically, serum concentrations of SN-38 may be reduced. CYP3A4 Inducers (Strong) may decrease the serum concentration of Irinotecan.
IsocarboxazidMay enhance the adverse/toxic effect of MAO Inhibitors.
IsoflurophateCarBAMazepine may increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.
IsomethepteneMay increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.
IsoniazidMay decrease the metabolism of CarBAMazepine.
IsradipineMay increase the metabolism of Calcium Channel Blockers (Dihydropyridine).
ItraconazoleCYP3A4 Inducers (Strong) may decrease the serum concentration of Itraconazole.
IvacaftorCYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.
IxabepiloneCYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.
LacosamideCarBAMazepine may enhance the AV-blocking effect of Lacosamide. CarBAMazepine may decrease the serum concentration of Lacosamide.
LamotrigineLamoTRIgine may enhance the adverse/toxic effect of CarBAMazepine. CarBAMazepine may increase the metabolism of LamoTRIgine.
LapatinibCYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.
LedipasvirP-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Ledipasvir.
LevonorgestrelMay diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.
LevothyroxineMay decrease the serum concentration of Thyroid Products.
LinagliptinCYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.
LinezolidMay enhance the adverse/toxic effect of MAO Inhibitors.
LiothyronineMay decrease the serum concentration of Thyroid Products.
LiotrixMay decrease the serum concentration of Thyroid Products.
LithiumCarBAMazepine may enhance the adverse/toxic effect of Lithium.
LopinavirCarBAMazepine may decrease the serum concentration of Lopinavir.
LoxapineLoxapine may increase serum concentrations of the active metabolite(s) of CarBAMazepine.
LULICONAZOLEMay increase the serum concentration of CYP3A4 Substrates.
LumefantrineCYP3A4 Inducers (Strong) may decrease the serum concentration of Lumefantrine.
LurasidoneCYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.
MACITENTANCYP3A4 Inducers (Strong) may decrease the serum concentration of Macitentan.
Magnesium SulfateMay enhance the CNS depressant effect of CNS Depressants.
MaravirocCYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.
MebendazoleCarBAMazepine may decrease the serum concentration of Mebendazole.
Medroxyprogesterone AcetateMay diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.
MefloquineMefloquine may diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants.
MestranolMay diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.
MethadoneMay increase the metabolism of Methadone.
MethazolamideCarbonic Anhydrase Inhibitors may increase the serum concentration of CarBAMazepine.
MethotrimeprazineCNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.
MethyclothiazideThiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.
MethylprednisoloneCYP3A4 Inducers (Strong) may decrease the serum concentration of MethylPREDNISolone.
MetolazoneThiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.
MetyrosineCNS Depressants may enhance the sedative effect of Metyrosine.
MianserinMay diminish the therapeutic effect of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Mianserin.
MifepristoneCYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.
MitotaneMay decrease the serum concentration of CYP3A4 Substrates.
MoclobemideMay enhance the adverse/toxic effect of MAO Inhibitors.
NabiloneMay enhance the CNS depressant effect of CNS Depressants.
NefazodoneCarBAMazepine may decrease the serum concentration of Nefazodone. Concentrations of active Nefazodone metabolites may also be reduced. Nefazodone may increase the serum concentration of CarBAMazepine. Also, concentrations of the active CarBAMazepine epoxide metabolite may be reduced.
NelfinavirMay increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.
NevirapineMay decrease the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of CarBAMazepine. This mechanism applies specifically to efavirenz.
NifedipineCYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.
NilotinibCYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.
NimodipineMay increase the metabolism of Calcium Channel Blockers (Dihydropyridine).
NisoldipineCYP3A4 Inducers (Strong) may decrease the serum concentration of Nisoldipine.
NorelgestrominMay diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.
NorethindroneMay diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.
NorgestimateMay diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.
NortriptylineMay increase the metabolism of Tricyclic Antidepressants.
OrlistatMay decrease the serum concentration of Anticonvulsants.
OrphenadrineCNS Depressants may enhance the CNS depressant effect of Orphenadrine.
OxcarbazepineCarBAMazepine may decrease serum concentrations of the active metabolite(s) of OXcarbazepine. Specifically, concentrations of the major active 10-monohydroxy metabolite may be reduced.
PaliperidoneCarBAMazepine may decrease the serum concentration of Paliperidone.
PanobinostatCYP3A4 Inducers (Strong) may decrease the serum concentration of Panobinostat.
ParoxetineMay increase the metabolism of Selective Serotonin Reuptake Inhibitors. Specifically those agents metabolized via CYP1A2, 2C, and/or 3A4 isoenzymes. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CarBAMazepine. Specifically those SSRIs that inhibit CYP3A4 isoenzymes.
PazopanibCYP3A4 Inducers (Strong) may decrease the serum concentration of PAZOPanib.
PerampanelCarBAMazepine may decrease the serum concentration of Perampanel.
PhenelzineMay enhance the adverse/toxic effect of MAO Inhibitors.
PhenytoinMay decrease the serum concentration of Phenytoin. CarBAMazepine may increase the serum concentration of Phenytoin. Possibly by competitive inhibition at sites of metabolism. Phenytoin may decrease the serum concentration of CarBAMazepine.
PirfenidoneCYP1A2 Inducers (Strong) may decrease the serum concentration of Pirfenidone.
PomalidomideCYP1A2 Inducers (Strong) may decrease the serum concentration of Pomalidomide.
PonatinibCYP3A4 Inducers (Strong) may decrease the serum concentration of PONATinib.
PramipexoleCNS Depressants may enhance the sedative effect of Pramipexole.
PraziquantelCYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.
PrednisoneCYP3A4 Inducers (Strong) may decrease the serum concentration of PredniSONE.
ProcarbazineMay enhance the adverse/toxic effect of MAO Inhibitors.
ProtriptylineMay increase the metabolism of Tricyclic Antidepressants.
QuetiapineMay increase serum concentrations of the active metabolite(s) of CarBAMazepine. CarBAMazepine may decrease the serum concentration of QUEtiapine.
QuinineMay decrease the serum concentration of QuiNINE. QuiNINE may increase the serum concentration of CarBAMazepine.
RanolazineCYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.
RasagilineMay enhance the adverse/toxic effect of MAO Inhibitors.
RegorafenibCYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.
RilpivirineMay decrease the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of CarBAMazepine. This mechanism applies specifically to efavirenz.
RisperidoneCarBAMazepine may decrease the serum concentration of RisperiDONE.
RitonavirMay increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.
RivaroxabanCYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.
RoflumilastCYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast.
RomidepsinCYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin.
RotigotineCNS Depressants may enhance the sedative effect of Rotigotine.
RufinamideCarBAMazepine may decrease the serum concentration of Rufinamide. Rufinamide may decrease the serum concentration of CarBAMazepine.
SaquinavirMay increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.
SaxagliptinCYP3A4 Inducers may decrease the serum concentration of Saxagliptin.
SelegilineMay enhance the adverse/toxic effect of MAO Inhibitors.
SertralineMay increase the metabolism of Selective Serotonin Reuptake Inhibitors. Specifically those agents metabolized via CYP1A2, 2C, and/or 3A4 isoenzymes. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CarBAMazepine. Specifically those SSRIs that inhibit CYP3A4 isoenzymes.
SiltuximabMay decrease the serum concentration of CYP3A4 Substrates.
SimeprevirCarBAMazepine may increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.
SofosbuvirP-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Sofosbuvir.
SorafenibCYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.
SulfisoxazoleMacrolide Antibiotics may decrease the metabolism of CarBAMazepine.
SunitinibCYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.
SuvorexantCYP3A4 Inducers (Strong) may decrease the serum concentration of Suvorexant.
TadalafilCYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.
TapentadolMay enhance the CNS depressant effect of CNS Depressants.
Tedizolid PhosphateMay enhance the adverse/toxic effect of MAO Inhibitors.
TelaprevirCarBAMazepine may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of CarBAMazepine.
TelithromycinMacrolide Antibiotics may decrease the metabolism of CarBAMazepine.
TemsirolimusCarBAMazepine may decrease the serum concentration of Temsirolimus. Concentrations of the active metabolite, sirolimus, are also likely to be decreased (and maybe to an even greater degree).
ThalidomideCNS Depressants may enhance the CNS depressant effect of Thalidomide.
TheophyllineTheophylline Derivatives may decrease the serum concentration of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Theophylline Derivatives.
TicagrelorCYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.
TipranavirMay increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.
TocilizumabMay decrease the serum concentration of CYP3A4 Substrates.
TofacitinibCYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib.
TolvaptanCYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.
TopiramateMay decrease the serum concentration of Topiramate.
ToremifeneCYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.
TrabectedinCYP3A4 Inducers (Strong) may decrease the serum concentration of Trabectedin.
TramadolTraMADol may enhance the CNS depressant effect of CarBAMazepine. TraMADol may diminish the therapeutic effect of CarBAMazepine. CarBAMazepine may decrease the serum concentration of TraMADol.
TranylcypromineMay enhance the adverse/toxic effect of MAO Inhibitors.
TreprostinilCYP2C8 Inducers (Strong) may decrease the serum concentration of Treprostinil.
UlipristalCYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.
Valproic AcidValproic Acid and Derivatives may increase serum concentrations of the active metabolite(s) of CarBAMazepine. Parent carbamazepine concentrations may be increased, decreased, or unchanged. CarBAMazepine may decrease the serum concentration of Valproic Acid and Derivatives.
VandetanibCYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.
VecuroniumCarBAMazepine may decrease the serum concentration of Vecuronium.
VemurafenibCYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.
VilazodoneCYP3A4 Inducers (Strong) may decrease the serum concentration of Vilazodone.
VorapaxarCYP3A4 Inducers (Strong) may decrease the serum concentration of Vorapaxar.
VoriconazoleCarBAMazepine may decrease the serum concentration of Voriconazole.
ZiprasidoneMay decrease the serum concentration of Ziprasidone.
ZolpidemZolpidem may enhance the CNS depressant effect of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Zolpidem.
ZuclopenthixolCYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.
Food Interactions
  • Avoid alcohol.
  • Avoid taking grapefruit or grapefruit juice throughout treatment.
  • Grapefruit can significantly increase serum levels of this product.
  • Take with food, increases availability and reduces irritation.

Targets

1. Sodium channel protein type 5 subunit alpha

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Sodium channel protein type 5 subunit alpha Q14524 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Yang YC, Huang CS, Kuo CC: Lidocaine, carbamazepine, and imipramine have partially overlapping binding sites and additive inhibitory effect on neuronal na+ channels. Anesthesiology. 2010 Jul;113(1):160-74. Pubmed
  4. Yang YC, Kuo CC: Inhibition of Na(+) current by imipramine and related compounds: different binding kinetics as an inactivation stabilizer and as an open channel blocker. Mol Pharmacol. 2002 Nov;62(5):1228-37. Pubmed
  5. Lipkind GM, Fozzard HA: Molecular model of anticonvulsant drug binding to the voltage-gated sodium channel inner pore. Mol Pharmacol. 2010 Oct;78(4):631-8. Epub 2010 Jul 19. Pubmed

Enzymes

1. Cytochrome P450 3A4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inducer

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Urichuk L, Prior TI, Dursun S, Baker G: Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 Jun;9(5):410-8. Pubmed
  2. Levy RH: Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia. 1995;36 Suppl 5:S8-13. Pubmed
  3. Cazali N, Tran A, Treluyer JM, Rey E, d’Athis P, Vincent J, Pons G: Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. Br J Clin Pharmacol. 2003 Nov;56(5):526-36. Pubmed
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

2. Cytochrome P450 2C8

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inducer

Components

Name UniProt ID Details
Cytochrome P450 2C8 P10632 Details

References:

  1. Cazali N, Tran A, Treluyer JM, Rey E, d’Athis P, Vincent J, Pons G: Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. Br J Clin Pharmacol. 2003 Nov;56(5):526-36. Pubmed
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

3. Cytochrome P450 1A2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor inducer

Components

Name UniProt ID Details
Cytochrome P450 1A2 P05177 Details

References:

  1. Wang B, Zhou SF: Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218. Pubmed
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

4. Cytochrome P450 2C9

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inducer

Components

Name UniProt ID Details
Cytochrome P450 2C9 P11712 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

5. Cytochrome P450 2C19

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor inducer

Components

Name UniProt ID Details
Cytochrome P450 2C19 P33261 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

6. Cytochrome P450 2B6

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inducer

Components

Name UniProt ID Details
Cytochrome P450 2B6 P20813 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

7. Cytochrome P450 3A5

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inducer

Components

Name UniProt ID Details
Cytochrome P450 3A5 P20815 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

8. Cytochrome P450 3A7

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A7 P24462 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

9. UDP-glucuronosyltransferase 2B7

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
UDP-glucuronosyltransferase 2B7 P16662 Details

References:

  1. Kim KA, Oh SO, Park PW, Park JY: Effect of probenecid on the pharmacokinetics of carbamazepine in healthy subjects. Eur J Clin Pharmacol. 2005 Jun;61(4):275-80. Epub 2005 May 25. Pubmed

Transporters

1. Multidrug resistance protein 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor inducer

Components

Name UniProt ID Details
Multidrug resistance protein 1 P08183 Details

References:

  1. Geick A, Eichelbaum M, Burk O: Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001 May 4;276(18):14581-7. Epub 2001 Jan 31. Pubmed
  2. Owen A, Pirmohamed M, Tettey JN, Morgan P, Chadwick D, Park BK: Carbamazepine is not a substrate for P-glycoprotein. Br J Clin Pharmacol. 2001 Apr;51(4):345-9. Pubmed
  3. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. Pubmed
  4. Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Loscher W: Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007 Feb;52(2):333-46. Epub 2006 Oct 10. Pubmed
  5. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. Pubmed

2. RalA-binding protein 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
RalA-binding protein 1 Q15311 Details

References:

  1. Awasthi S, Hallene KL, Fazio V, Singhal SS, Cucullo L, Awasthi YC, Dini G, Janigro D: RLIP76, a non-ABC transporter, and drug resistance in epilepsy. BMC Neurosci. 2005 Sep 27;6:61. Pubmed

3. Canalicular multispecific organic anion transporter 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Canalicular multispecific organic anion transporter 1 Q92887 Details

References:

  1. Ufer M, Mosyagin I, Muhle H, Jacobsen T, Haenisch S, Hasler R, Faltraco F, Remmler C, von Spiczak S, Kroemer HK, Runge U, Boor R, Stephani U, Cascorbi I: Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 -24C>T polymorphism in young and adult patients with epilepsy. Pharmacogenet Genomics. 2009 May;19(5):353-62. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:11